HR and breast cancer: The aim of this study was therefore to assess the cost-effectiveness of the Oncotype DX® test compared to standard of care (SoC; involving clinicopathological risk assessment only) among patients in France with HR+, HER2−, early BC who were considered at high clinicopathological risk of distant recurrence.